Last updated: February 28, 2026
What is Streptozocin?
Streptozocin (also called zenostatin) is an alkylating agent primarily used in chemotherapy to treat pancreatic neuroendocrine tumors (PNET) and islet cell carcinomas. It is an antibiotic derived from Streptomyces achromogenes with cytotoxic effects on insulin-producing pancreatic islet cells. Its market has been limited primarily to niche oncology indications.
Market Landscape
| Aspect |
Details |
| Market Size (2022) |
Estimated at approximately $125 million globally. |
| Growth Rate (CAGR 2022-2027) |
Projected around 4%. |
| Key Players |
GlaxoSmithKline (GSK) historically supplied streptozocin; now limited to compounding pharmacies and specialty distributors due to age and manufacturing constraints. |
| Approved Indications |
Pancreatic neuroendocrine tumors; rare use in insulinoma. |
| Off-label Use |
Experimental treatments for other tumors. |
Manufacturing and Supply Constraints
| Factor |
Impact |
| Manufacturing Attrition |
Older production processes with reduced yields limit availability. |
| Patent Status |
Patent has been expired for decades; no exclusivity. |
| Regulatory Status |
No current FDA approval for new uses; marketed as an investigational or compounded drug in many jurisdictions. |
| Supply Chain |
Limited due to discontinuation by original manufacturers, reliance on small-scale producers. |
Regulatory and Patent Landscape
| Point |
Details |
| Patent Expiry |
Patent expired in the 1980s. |
| FDA Status |
Approved for use in specific oncology indications. No recent new-drug applications filed. |
| Orphan Drug Status |
Not designated as orphan drug; market size below threshold for incentives. |
R&D and Clinical Pipeline
| Status |
Details |
| Investigational Use |
Growing research into alternative delivery methods, combination therapies, and novel indications. |
| Clinical Trials |
Limited phase I/II trials exploring new applications. |
| Investment in R&D |
Historically low; R&D largely driven by academic institutions or small biotech companies with limited funding. |
Competitive and Market Dynamics
| Aspect |
Analysis |
| Competition |
Other agents such as everolimus, sunitinib, and peptide receptor radionuclide therapy (PRRT) often preferred for neuroendocrine tumors, reducing streptozocin’s clinical dominance. |
| Cost |
Not commercially priced by major pharmaceutical companies; compounded versions may vary in cost and quality. |
| Reimbursement |
Complex; insurer coverage depends on indication and local policies. |
Investment Risks and Opportunities
| Risks |
Details |
| Manufacturing Stability |
Discontinuation risks due to aging production lines. |
| Regulatory Changes |
Potential restrictions or reclassification affecting use. |
| Market Size |
Niche indication limits revenue potential. |
| Competition |
Advances in targeted therapies reduce demand for older agents. |
| Opportunities |
Details |
| Orphan Indication Expansion |
Potential for new approvals in rare tumor types. |
| Novel Delivery |
Development of targeted delivery methods to improve efficacy and reduce toxicity. |
| Collaborations |
Partnering with biotech for R&D initiatives. |
| Market Niche |
Limited competition in compassionate use or specialized settings. |
Financial Outlook
| Aspect |
Implication |
| Revenue Potential |
Modest, constrained by small market size and supply issues. |
| Investment Horizon |
Longer-term, dependent on successful reformulation, new indications, or regulatory approval. |
| Profitability |
Limited current profitability; potential future upside with market expansion. |
Regulatory Outlook
| Potential Changes |
Impact |
| Regulatory Incentives |
Lack of current incentives reduces interest. |
| Safety and Efficacy |
Ongoing research could support expanded use, influencing regulatory decisions. |
| Manufacturing Approval |
New manufacturing approvals would stabilize supply. |
Key Takeaways
- Streptozocin's current market is niche, limited by manufacturing constraints and competition from newer agents.
- Supply disruption and patent expiration contribute to market uncertainty.
- Future opportunities hinge on R&D, potential new indications, and manufacturing reformulation.
- Financial viability remains limited without significant market expansion or regulatory support.
FAQs
1. Can streptozocin be repurposed for other cancers?
Potential exists, but largely dependent on clinical trials demonstrating safety and efficacy for new indications.
2. Are there ongoing efforts to improve streptozocin manufacturing?
Yes. Small biotech and academic institutions aim to develop alternative synthesis methods, but commercial-scale production remains limited.
3. What are the main competitors to streptozocin in neuroendocrine tumor treatment?
Agents like everolimus, sunitinib, and peptide receptor radionuclide therapy have taken precedence due to better efficacy profiles.
4. Is streptozocin available in generic form?
Yes, in some markets, but supply is inconsistent due to manufacturing limitations.
5. What milestones could enhance streptozocin’s market prospects?
New clinical evidence supporting broader or additional indications, regulatory approval for reformulated versions, or manufacturing breakthroughs.
References
- Kvols, L. K. (2014). Treatment of neuroendocrine tumors. Cancer Treatment Reviews, 40(7), 687–696.
- National Cancer Institute. (2022). Streptozocin. Drug information.
- U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations.
- Squires, D., & Moore, M. (2015). The history of streptozocin. Oncology & Hematology Reviews, 10(2), 52–55.
- Wiedenmann, B., & Rogenhofer, S. (2017). Management of pancreatic neuroendocrine neoplasms. Gut and Liver, 11(2), 184–193.
[1] Kvols, L. K. (2014). Treatment of neuroendocrine tumors. Cancer Treatment Reviews, 40(7), 687–696.
[2] National Cancer Institute. (2022). Streptozocin. Drug information.
[3] U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations.
[4] Squires, D., & Moore, M. (2015). The history of streptozocin. Oncology & Hematology Reviews, 10(2), 52–55.
[5] Wiedenmann, B., & Rogenhofer, S. (2017). Management of pancreatic neuroendocrine neoplasms. Gut and Liver, 11(2), 184–193.
